Incidence, risk factors, and clinical outcomes of peripartum cardiomyopathy in Hong Kong
Hong Kong Medical Journal · 2025
DOI: 10.12809/hkmj2512986 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Hong Kong Medical Journal, 2025. Verfasst von L S K Law und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynaecology, Tuen Mun Hospital, Hong Kong SAR, China. Hauptthemen laut MEDLINE: Pregnancy Complications, Cardiovascular, Cardiomyopathies, Puerperal Disorders. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
INTRODUCTION: Peripartum cardiomyopathy (PPCM) is an uncommon but serious form of heart failure affecting women during late pregnancy or early postpartum. This territory-wide multicentre retrospective study aimed to evaluate the local incidence, risk factors, and clinical outcomes, including subsequent pregnancies, in Hong Kong. METHODS: Medical records were retrospectively reviewed for women who delivered at all public hospitals between 1 January 2013 and 31 December 2022 and met the 2010 European Society of Cardiology Working Group criteria for PPCM. Regression analysis was performed to investigate maternal risk factors. RESULTS: Thirty Asian women were diagnosed with PPCM, corresponding to an incidence of 1 in 11 179 live births. Eleven (36.7%) had antepartum onset of symptoms, and 25 (83.3%) were diagnosed after childbirth, most presenting with severe symptoms (90%). The median left ventricular ejection fraction was 30% (range, 10%-44%). Notable complications included cardiogenic shock (10%), respiratory failure (23.3%), acute renal failure (23.3%), and thromboembolism (23.3%). Most women received guideline-directed heart failure therapy. At 12 months, all-cause mortality was 6.7%, and cardiac recovery occurred in 60%. Eleven women had 13 subsequent pregnancies (three miscarriages, five terminations, and five live births). There were no maternal deaths or cases of recurrent PPCM. Genetic testing identified potentially pathogenic variants in at least 10% of women. Antenatal anaemia (adjusted odds ratio [OR]=13.04; 95% confidence interval [95% CI]=3.72-45.70) and hypertensive disorders of pregnancy (adjusted OR=38.00; 95% CI=9.66-149.52) were associated with higher odds of PPCM. CONCLUSION: This study highlights the substantial morbidity and mortality associated with PPCM. Genetic testing may aid in risk stratification and prognostication.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Obstetrics and Gynaecology, Tuen Mun Hospital, Hong Kong SAR, China.
- Department of Obstetrics and Gynaecology, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong SAR, China.
- Department of Obstetrics and Gynaecology, Kwong Wah Hospital, Hong Kong SAR, China.
- Department of Obstetrics and Gynaecology, Queen Elizabeth Hospital, Hong Kong SAR, China.
- Department of Obstetrics and Gynaecology, Princess Margaret Hospital, Hong Kong SAR, China.
- Department of Obstetrics and Gynaecology, Pamela Youde Nethersole Eastern Hospital, Hong Kong SAR, China.
Zitieren
APA
Law, L. S. K., Kwong, L. T., Siong, K. H., Wong, S. T. K., Chan, W. L., Tse, K. Y., Chan, Y. Y. Y., Eu, K. S., Chow, C. Y., Wai, J. K. O., Mok, H. C., & So, P. L. (2025). Incidence, risk factors, and clinical outcomes of peripartum cardiomyopathy in Hong Kong. Hong Kong Medical Journal. https://doi.org/10.12809/hkmj2512986
Vancouver
Law LSK, Kwong LT, Siong KH, Wong STK, Chan WL, Tse KY, et al. Incidence, risk factors, and clinical outcomes of peripartum cardiomyopathy in Hong Kong. Hong Kong Medical Journal. 2025. doi:10.12809/hkmj2512986
BibTeX
@article{Law2025,
author = {Law, L S K and Kwong, L T and Siong, K H and Wong, S T K and Chan, W L and Tse, K Y and Chan, Y Y Y and Eu, K S and Chow, C Y and Wai, J K O and Mok, H C and So, P L},
title = {Incidence, risk factors, and clinical outcomes of peripartum cardiomyopathy in Hong Kong},
journal = {Hong Kong Medical Journal},
year = {2025},
doi = {10.12809/hkmj2512986}
}
EUVIMED